- Trials with a EudraCT protocol (224)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
224 result(s) found for: Working level.
Displaying page 1 of 12.
EudraCT Number: 2010-019897-33 | Sponsor Protocol Number: 2522518514 | Start Date*: 2011-04-14 |
Sponsor Name:erasmus mc | ||
Full Title: Selective D1 activation by addition of L-Dopa to antipsychotic treatment in patients with schizophrenia | ||
Medical condition: patients with psychotic symptoms, diagnosed with schizophrenia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004172-17 | Sponsor Protocol Number: ETES | Start Date*: 2021-04-26 |
Sponsor Name:Medizinische Universität Innsbruck | ||
Full Title: Electroconvulsive therapy vs. esketamine nasal spray in treatment-resistant depression: a longitudinal, randomized efficacy comparison pilot study | ||
Medical condition: treatment resistant depression | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-001976-75 | Sponsor Protocol Number: 20130385 | Start Date*: 2014-09-11 | ||||||||||||||||
Sponsor Name:Amgen Inc | ||||||||||||||||||
Full Title: A Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Evolocumab on Cognitive Function in Patients with Clinically Evident Cardiovascular Disease and Receiving Statin Back... | ||||||||||||||||||
Medical condition: Dyslipidemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) GR (Completed) IT (Completed) FI (Completed) EE (Completed) SK (Completed) LV (Completed) DE (Completed) LT (Completed) CZ (Completed) PT (Completed) BE (Completed) HU (Completed) DK (Completed) ES (Completed) NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-001459-35 | Sponsor Protocol Number: MC/PR/1400/007/11 | Start Date*: 2012-12-20 | |||||||||||
Sponsor Name:CHIESI | |||||||||||||
Full Title: MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY ON THE THERAPEUTIC EFFICACY AND SAFETY OF BECLOMETHASONE DIPROPIONATE SUSPENSION FOR INHALATION 800 micrograms TWICE... | |||||||||||||
Medical condition: Acute rhinosinusitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002429-12 | Sponsor Protocol Number: UC_0160/1613 | Start Date*: 2018-01-31 |
Sponsor Name:UNICANCER | ||
Full Title: PERSONALIZED TREATMENT OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER PATIENTS ACCORDING TO CIRCULATING TUMOR CELLS KINETIC DURING CHEMOTHERAPY | ||
Medical condition: Metastatic castrate-resistant prostate cancer requiring initiation of chemotherapy | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-000156-11 | Sponsor Protocol Number: S65914 | Start Date*: 2022-02-25 |
Sponsor Name:KU Leuven | ||
Full Title: Oxytocin and the development of attachment: Looking beyond the expected? | ||
Medical condition: General healthy population children (ages 8 - 13 years old). | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003825-27 | Sponsor Protocol Number: 263CS201 | Start Date*: 2020-06-02 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004862-24 | Sponsor Protocol Number: ESBA105CRD04 | Start Date*: 2009-01-02 | |||||||||||
Sponsor Name:ESBATech, an Alcon Biomedical Research Unit LLC | |||||||||||||
Full Title: An open-label exploratory study to assess the safety, tolerability and clinical activity of topically applied ESBA105 in patients with acute anterior uveitis | |||||||||||||
Medical condition: Acute, unilateral anterior uveitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003139-47 | Sponsor Protocol Number: EFC15992 | Start Date*: 2021-06-17 | |||||||||||
Sponsor Name:Sanofi-Aventis Recherche & Développement | |||||||||||||
Full Title: A Phase 3 randomized, open label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smo... | |||||||||||||
Medical condition: Smoldering Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) SE (Completed) NO (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) DE (Trial now transitioned) LT (Trial now transitioned) HU (Trial now transitioned) FR (Trial now transitioned) GR (Trial now transitioned) IE (Completed) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005382-79 | Sponsor Protocol Number: FIL-BBV | Start Date*: 2015-09-15 | ||||||||||||||||
Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS | ||||||||||||||||||
Full Title: A phase II study with bendamustine plus brentuximab vedotin in Hodgkin’s lymphoma and CD30 + peripheral T-cell lymphoma in first salvage setting: the BBV regimen. | ||||||||||||||||||
Medical condition: Hodgkin’s lymphoma and CD30+ peripheral T-cell lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004758-27 | Sponsor Protocol Number: IVIGPANSOpen | Start Date*: 2020-03-02 |
Sponsor Name:Gillberg Neuropsychiatry Centre | ||
Full Title: Intravenous immunoglobulin (IVIG) treatment in children with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS): an open-label trial in South-western Sweden | ||
Medical condition: Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) is a research diagnosis given to patients who have an abrupt, dramatic onset of neuropsychiatric symptoms including obsessions/compulsions and... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-000054-28 | Sponsor Protocol Number: OLIGOTREAT | Start Date*: 2023-06-02 | |||||||||||
Sponsor Name:Klinikum der Universität München | |||||||||||||
Full Title: Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity (OligoTreat) | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001822-23 | Sponsor Protocol Number: CEPO906A2229 | Start Date*: 2006-07-29 |
Sponsor Name:Novartis Farmacéutica, S.A. | ||
Full Title: A Randomized Multicenter Phase II Trial of Patupilone (EPO906) plus Prednisone versus Docetaxel (Taxotere) plus Prednisone in Patients with Metastatic Hormone Refractory Prostate Cancer | ||
Medical condition: Cancer of the prostate is the most commonly diagnosed neoplasm in men in the United States after skin cancer. In 2002, over 189,000 new cases were diagnosed in United States representing 30% of all... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: ES (Completed) DE (Completed) BE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005629-65 | Sponsor Protocol Number: RG_12-269 | Start Date*: 2014-01-15 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: Management of Transformed Chronic myeloid leukaemia: Ponatinib and Intensive chemotherapy: a dose finding study | |||||||||||||
Medical condition: Chronic Myeloid Leukaemia (CML) in Blast Phase | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001541-24 | Sponsor Protocol Number: NeuroIPT-1 | Start Date*: 2016-03-07 |
Sponsor Name:University Medical Center Freiburg | ||
Full Title: Neuroenhancement of Interpersonal Psychotherapy in Major Depression | ||
Medical condition: Major Depression (ICD-10; F32.2/F33.2) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-001839-23 | Sponsor Protocol Number: 14137A | Start Date*: 2012-05-14 |
Sponsor Name:H. Lundbeck A/S | ||
Full Title: Interventional randomised, double-blind, parallel-group, placebo-controlled, exploratory study investigating the effects of Lu AA21004 on cognition and BOLD fMRI signals in subjects remitted fro... | ||
Medical condition: Cognitive dysfunction Major depressive disorder (MDD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000312-15 | Sponsor Protocol Number: P150902 | Start Date*: 2016-08-12 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Treatment tapering in oligoarticular or rheumatoid factor negative polyarticular Juvenile Idiopathic Arthritis with inactive disease on biologic therapy | |||||||||||||
Medical condition: Patients with oligoarticular onset or rheumatoid factor negative polyarticular JIA followed in tertiary care center for paediatric rheumatology. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001263-23 | Sponsor Protocol Number: BP27832 | Start Date*: 2014-03-19 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF RO5186582 IN ADULTS AND ADOLESCENTS WITH DOWN SYNDROME (CLEMATIS) | |||||||||||||
Medical condition: Down Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000459-41 | Sponsor Protocol Number: PSMA-617-01 | Start Date*: 2018-09-04 | |||||||||||
Sponsor Name:Endocyte, Inc., A Novartis Company | |||||||||||||
Full Title: VISION: An international, prospective, open label, multicenter, randomized Phase 3 study of 177LU-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistan... | |||||||||||||
Medical condition: PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) SE (Completed) FR (Completed) DK (Completed) NL (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016068-35 | Sponsor Protocol Number: DRI11073 | Start Date*: 2010-02-19 | |||||||||||
Sponsor Name:Sanofi-aventis Recherche & Développement | |||||||||||||
Full Title: A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS) | |||||||||||||
Medical condition: Ankylosing Spondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) FR (Completed) HU (Completed) ES (Completed) LT (Completed) AT (Completed) CZ (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
